Ligand Pharmaceuticals Plans Financial Results Announcement
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is preparing to report its financial results for the second quarter of 2025. The report is scheduled to be released on a Thursday in early August, kicking off a day designed for investors and analysts to gain insight into the company's performance and strategies moving forward.
Conference Call Details
On the same day as the financial report, Ligand will host a conference call at 8:30 AM Eastern Time. This call serves as an opportunity for the management team to discuss the results in-depth and share broader updates on the business operations of Ligand. Investors and interested parties are encouraged to participate in this informative session.
How to Access the Call
Those wishing to tune into the conference call can do so by dialing the following numbers: (800) 715-9871 for callers within the U.S. and Canada and (646) 307-1963 for international participants. When prompted, use the Conference ID 3661098 to gain access. Additionally, live webcasts of the call will be available, enhancing accessibility for all stakeholders.
Understanding Ligand's Business Model
Ligand Pharmaceuticals is recognized in the biopharmaceutical sector for its unique approach to enabling scientific progression. The company funds and supports the development of high-value medications through an innovative business model that focuses on licensing and financing. This strategy aims to create a diversified portfolio of revenue streams from biotechnology and pharmaceutical products.
Innovative Technology Platforms
Central to Ligand's success are its distinctive technology platforms, including the well-known Captisol® system. This platform is designed to enhance the solubility and stability of various drugs, making it a vital tool in their arsenal. Furthermore, the NITRICIL™ platform gives Ligand the ability to produce formulations that can adjust dosage over time, which is essential for addressing a wide range of medical conditions.
Partnerships with Leading Pharma Companies
Ligand has forged strong alliances with top-tier pharmaceutical firms such as Amgen, Merck, and Pfizer, among others. By leveraging the strengths of these industry leaders in late-stage development and commercialization, Ligand is positioned to maximize its revenue potential while minimizing operational costs.
Investor Engagement and Communication
Effective communication with investors is a priority for Ligand Pharmaceuticals. The company utilizes its investor relations webpage alongside its social media platforms to disseminate essential information to stakeholders. Ligand encourages investors to stay updated through its official website, social media accounts, SEC filings, and conference calls, fostering transparency and engagement.
Contact Information for Stakeholders
For inquiries, Ligand provides direct contact methods. Investors can reach out to Melanie Herman via email at investors@ligand.com or by calling (858) 550-7761. Media contacts are also available, with Kellie Walsh reachable at media@ligand.com and phone number (914) 315-6072.
Frequently Asked Questions
When will Ligand Pharmaceuticals announce its Q2 2025 financial results?
Ligand is set to announce its financial results for the second quarter of 2025 on August 7.
What time is the conference call scheduled?
The conference call will take place at 8:30 AM Eastern Time on the same day as the financial results announcement.
How can I participate in the conference call?
Participants can join by calling (800) 715-9871 for U.S. and Canadian callers or (646) 307-1963 for international callers, using the Conference ID 3661098.
What technologies does Ligand Pharmaceuticals specialize in?
Ligand is known for its Captisol® and NITRICIL™ platforms, which enhance drug solubility and allow adjustable dosing options respectively.
Who are some of Ligand's partners in the pharmaceutical industry?
Ligand collaborates with leading companies such as Amgen, Merck, and Pfizer to leverage their capabilities in drug development and commercialization.
